ProStrakan extend deal with Orexo for Rapinyl

ProStrakan have extended its existing European licensing agreement for Rapinyl with its Swedish partner Orexo to include North America.

FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Exforge more effective than amlodipine alone

Exforge (valsartan/amlodipine) treatment results near twice as effective as amlodipine alone at reducing patients with high baseline blood pressure to a healthier blood pressure goal

Merck publish discovery of Nicotinic receptor partial agonist MK-0354

Merck have published the synthesis and preclinical data on nicotinic receptor partial agonist MK-0354

Othera file IND for OT-730 in Glaucoma

Othera have submitted an IND to the FDA to initiate clinical trials with beta blocker OT-730 for the treatment of glaucoma

Memory Pharmaceuticals report positive preclinical data for 5-HT6 antagonist

Alzheimer’s Association International Conference show Memory Pharmaceutical’s 5-HT6 antagonist MEM 68626 to demonstate effecacy in animal models of cognition

Tracleer (bosentan) approved in EU for Pulmonary Arterial Hypertension

Actelion Ltd have announced today that its endothelin receptor antagonist Tracleer (bosentan) has been approved in the EU for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH)